Solid Biosciences reveals upgraded clinical hold for gene therapy – BioPharma Dive
|
Solid Biosciences reveals upgraded clinical hold for gene therapy
BioPharma Dive Solid Biosciences Inc. announced that the Food and Drug Administration has placed its Phase 1/2 Duchenne Muscular Dystrophy (DMD) trial on full clinical hold weeks after the first patient was treated. That patient in the IGNITE DMD study received 5E13 … |
